CareDx CEO John Walter Hanna Jr. sold 19,480 shares on January 21-22, 2026, totaling approximately $412,200 at an average price of $21.16 per share through a pre-planned Rule 10b5-1 trading plan. The sale reduced his direct holdings by 3.16%, leaving him with 597,405 shares. The article notes this shouldn't concern investors, as the company reported strong Q4 2025 preliminary results with $108 million in revenue (25% YoY growth) and expects continued growth in 2026 from its testing solutions.

Johnson Fistel, a law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. for potential breaches of fiduciary duties and violations of federal securities laws. The investigation is related to CareDx's issuance of false and misleading public statements regarding its compliance with healthcare laws and revenue growth, which led to a significant drop in the company's stock price.

The law firm Morris Kandinov is investigating several companies, including CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc., for potential breaches of fiduciary duties and other legal violations on behalf of shareholders.

Morris Kandinov, a national law firm, is investigating potential breaches of fiduciary duties and other legal violations by CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc. Shareholders are encouraged to contact the firm to learn more about their rights.

The liquid biopsy market is experiencing significant growth, driven by advancements in technology and increasing demand for non-invasive diagnostic methods. North America is the largest market, with a 48.11% share in 2023. Key drivers include increased benefits over conventional biopsy, rising cancer incidence, and technological advancements, while high costs and shortage of skilled professionals pose challenges.

This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.

The article analyzes the recent analyst ratings and price targets for CareDx, a precision medicine company focused on transplant patients. It highlights the company's financial performance, including revenue decline, strong profitability, and high debt levels.

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 0 0 0 0 0 1M Ago 4 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.5, a high estimate of $22.00, and a low estimate of $14.00. Observing a 26.92% increase, the current average has risen from the previous average price target of $13.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of CareDx by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Connor Chamberlain Craig-Hallum Raises Buy $22.00 $15.00 Matthew Sykes Goldman Sachs Raises Buy $14.00 $10.00 Mason Carrico Stephens & Co. Raises Overweight $18.00 $15.00 Connor Chamberlain Craig-Hallum Maintains Buy $15.00 - Alexander Nowak Craig-Hallum Raises Buy $15.00 $12.00 Mason Carrico Stephens & Co. Maintains Overweight $15.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Providing a comprehensive analysis, analysts offer qualitative ...Full story available on Benzinga.com

Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:CDNA), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 1 0 0 0 1M Ago 2 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.4, along with a high estimate of $18.00 and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 24.9% from the previous average price target of $12.33. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Matthew Sykes Goldman Sachs Raises Buy $14.00 $10.00 Mason Carrico Stephens & Co. Raises Overweight $18.00 $15.00 Connor Chamberlain Craig-Hallum Maintains Buy $15.00 - Alexander Nowak Craig-Hallum Raises Buy $15.00 $12.00 Mason Carrico Stephens & Co. Maintains Overweight $15.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Unveiling insights, ...Full story available on Benzinga.com

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biodesix (BDSX) delivered earnings and revenue surprises of 6.67% and 5.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.